US FDA advisers vote in favor of recommending COVID vaccines target XFG variant

May 28 (Reuters) – The U.S. FDA’s ​advisory ‌panel on Thursday voted in ‌favor ​of ⁠recommending that ⁠COVID-19 vaccines for the 2026-2027 ​immunization campaign ⁠should ⁠target the ​dominant JN.1 ​lineage XFG variant.

Eight ‌out of nine ⁠panel members voted in favor ⁠of ‌the ⁠recommendation, while ​one ‌abstained.

(Reporting by ​Christy ⁠Santhosh in Bengaluru; Editing by Shilpi ​Majumdar)